论文部分内容阅读
目的:探讨注射用唑来膦酸(密固达)对维、汉民族绝经期后女性骨质疏松患者骨密度(BMD)的影响的差别。方法:将71例绝经期后女性骨质疏松患者,按照民族分为维族骨质疏松组(34例)和汉族骨质疏松组(37例),采用双能X线骨密度仪(DEXA)检测两组用药前1天和用药后1年后腰椎(L2～4)椎体及髋部的BMD。结果:维族骨质疏松组患者用药后1年腰椎BMD上升1.6%,髋部BMD上升1.4%;汉族骨质疏松患者用药后1年腰椎BMD上升2.2%,髋部BMD上升2.7%;汉族骨质疏松组患者的腰椎、髋部提高率高于维族骨质疏松组患者(P<0.05)。结论:应用唑来膦酸注射液可明显提高维、汉族绝经后骨质疏松妇女骨密度。应用唑来膦酸注射液汉族骨质疏松,汉族患者效果优于维族患者。
OBJECTIVE: To investigate the difference of bone mineral density (BMD) after injection of zoledronic acid (Miunda) in women with osteoporosis after menopause. Methods: Seventy-one postmenopausal women with osteoporosis were divided into Uygur osteoporosis group (n = 34) and Han osteoporosis group (n = 37) according to ethnic group. The patients were diagnosed by DEXA BMD of vertebral body and hip of lumbar vertebra (L2 ~ 4) one day before treatment and one year after treatment. Results: The BMD of lumbar vertebrae increased by 1.6% and the hip BMD increased by 1.4% at 1 year after treatment in Uighur osteoporosis patients. The BMD of lumbar spine increased by 2.2% and the hip BMD increased by 1% at 1 year after treatment in Han nationality osteoporosis patients. The lumbar spine and hip in the loose group were higher than those in the Uighur osteoporosis group (P <0.05). Conclusion: Zoledronic acid injection can significantly increase the bone mineral density in the Han and Han nationality postmenopausal women with osteoporosis. Application of zoledronic acid injection Han osteoporosis, Han patients better than Uygur patients.